Carregant...
Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma
Multiple myeloma (MM) is a heterogeneous disease with certain genetic features [eg, t(4;14), del17p] associated with worse outcome. The introduction of thalidomide, lenalidomide, and bortezomib has dramatically improved the outlook for patients with MM, but their relative benefit (or harm) for diffe...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society of Hematology
2013
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3567336/ https://ncbi.nlm.nih.gov/pubmed/23165477 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-05-432203 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|